BRISTOL-MYERS SQUIBB COMPANY Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of -11.70 million shares for the 12-month period ending 2012-12-31, per its 10-K filed 2013-02-15.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2013-02-15
- BRISTOL-MYERS SQUIBB COMPANY share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2012 was -11.70M shares.
- BRISTOL-MYERS SQUIBB COMPANY share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2011 was -10.80M shares, a 167.48% decline from fiscal 2010.
- BRISTOL-MYERS SQUIBB COMPANY share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2010 was 16.00M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|
| 2012-12-31 | -11.70M shares 10-K · filed 2013-02-15 |
| 2011-12-31 | -10.80M shares 10-K · filed 2012-02-17 |
| 2010-12-31 | 16.00M shares 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |